

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Abrams, 2006 ²²⁰	1032 Study Group.	Double-blind	Yes	Unclear	Adequate	No
Abrams, 1998 ²¹⁹	RCT	Double-blind	Yes	NR	Adequate	Yes
Abrams, 2008 ⁴⁷	Pooled	Double-blind	Yes	Previously reported ²⁵⁶	Adequate	No
Altan-Yaycioglu, 2005 ²²¹	RCT	Single blind	Not stated	Unclear	Adequate	No
Anderson, 1999 ³⁹¹ U.S. Food and Drug Administration, 1998 ⁴¹	OROS Oxybutynin Study Group	Double-blind	No	Not reported	Adequate	No
Appell, 1997 ²²²	Pooled	Double-blind	Yes	Unclear	Adequate	No
Appell, 2001 ²²³	OBJECT (Overactive Bladder: Judging Effective Control and Treatment)	Double-blind	Yes	Unclear	Adequate	No
Armstrong, 2005 ²²⁴	RCT	Double-blind	No	Previously reported ²²⁷	Previously reported ²²⁷	Previously reported ²²⁷
Armstrong, 2007 ²²⁵	Pooled	Double-blind	Yes	Previously reported ^{223,226,227}	Adequate	Previously reported ^{223,226,227}
Rios, 2007 ³⁶⁴	RCT	Double-blind	Yes	Unclear	No	Yes
Barkin, 2004 ²²⁸	UROMAX Study Group.	Double-blind	Yes	Unclear	Adequate	No
Bent, 2008 ²²⁹	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Birns, 2000 ²³⁰	The Oxybutynin CR Clinical Trial Study	Double-blind	Yes	Adequate	Adequate	Yes
Blom, 1995 ²³¹	RCT	Single blind	No	NR	NR	No
Bodeker, 2010 ²³²	Post-hoc	Double-blind	Reported previously ⁴¹⁷	Reported previously ⁴¹⁷	Adequate	Previously reported ⁴¹⁷
Brubaker, 2008 ²³³	Pelvic Floor Disorders Network.	Double-blind	Not stated	Unclear	Adequate	Yes
Brunton, 2010 ²³⁴	RCT	Double-Blind	NR	NR	Adequate	NR
Bump, 2003 ¹⁰³	Duloxetine Urinary Incontinence Study Group.	Double-blind	No	Previously reported ³⁵⁴	Adequate	Yes
Bump, 2008 ²³⁵	Pooled	Combination	Not stated	Previously reported ^{275,350,411}	Previously reported ^{275,350,411}	No
Burgio, 2001 ²³⁶	RCT	Double-blind	No	Unclear	Not reported	No

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Burgio, 2000 ²³⁷	RCT analysis	Double-blind	NR	NR	Not reported	No
Burgio, 1998 ²³⁸	RCT	Double-blind	Yes	Unclear	No	No
Burgio, 2008 ²³⁹	Urinary Incontinence Treatment Network	Open label	Yes	Unclear	Not reported	Yes
Burgio, 2010 ²⁴²	RCT	Open-label	Yes	NR	Not-adequate	Yes
But, 2010 ²⁴³	SOLIDAIR	Open-Label	Yes	NR	Not-adequate	NR
Cardozo, 2006 ⁴¹²	Pooled	Double-blind	No	Previously reported ⁵²	Adequate	Previously reported ⁵²
Cardozo, 2004 ²⁴⁵	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Cardozo, 2004 ⁵¹	RCT	Double-blind	No	Previously reported ⁵²	Adequate	Yes
Cardozo, 2010 ²⁴⁴	RCT followed by open-label	Double-blind	Yes	Adequate	Adequate	Yes
Cardozo, 2008 ⁶⁰	SUNRISE	Double-blind	Yes	NR	Adequate	Yes
Cartwright, 2011 ²⁴⁶	RCT	Not reported	Yes	Adequate	Adequate	Yes
Castro, 2008 ²⁴⁷	RCT	Single blind	No	NR	Not Adequate	Yes
Castro-Diaz, 2007 ²⁴⁸	Duloxetine Dose Escalation Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Chancellor, 2001 ²⁴⁹	RCT	Double-blind	No	NR	Adequate	No
Chancellor, 2008 ²⁵⁰	The ABLE trial	Open label	Yes	Adequate	Adequate	Yes
Chancellor, 2010 ²⁵¹	Post-hoc	Double-blind	NR	Unclear	NR	NR
Chapple, 2005 ²⁵²	RCT	Double-blind	No	Adequate	Adequate	Yes
Chapple, 2007 ²⁵³	RCT	Double-blind	No	Adequate	Adequate	No
Chapple, 2008 ²⁵⁴	RCT analysis	Double-blind	No	Adequate	Previously reported ²⁵³	No
Chapple, 2007 ²⁵⁵	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Chapple, 2005 ²⁵⁶	Pooled	Double-blind	Yes	Previously reported	Previously reported	No
Chapple, 2004 ²⁶⁰	RCT	Double-blind	Yes	NR	Adequate	Yes
Chapple, 2004 ²⁶¹	RCT	Double-blind	No	NR	NR	NR
Chapple, 2007 ²⁵⁵	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Chapple, 2007 ²⁵⁸	STAR study group	Double-blind	Yes	Adequate	Adequate	Previously reported ⁵⁸
Chapple, 2005 ⁵⁸	STAR study group	Double-blind	Yes	Adequate	Adequate	Yes
Chapple, 2006 ²⁵⁹	RCT	Single-blind	No	NR	Not adequate	Yes
Chapple, 2004 ⁵²	RCT	Double-blind	NR	NR	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Chompootawee, 1998 ²⁶²	RCT	NR	NR	Unclear	Adequate	No
Choo, 2008 ²⁶³	RCT	Double-blind	No	NR	Adequate	No
Chu, 2009 ²⁶⁴	RCT	Double-blind	No	Adequate	Adequate	Yes
Corcos, 2006 ²⁶⁵	Uromax Study Group	Double-blind	Yes	NR	Adequate	Yes
Corcos, 2011 ²⁶⁶	Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group	Double-blind	No	Unclear	Adequate	NR
Davilla, 2001 ²⁶⁷	Transdermal Oxybutynin Study Group	Double-blind	Not stated	Unclear	Adequate	Yes
Dessole, 2004 ²⁶⁸	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Diokno, 2003 ²²⁷ Anderson, 2006 ²⁷⁰ Chu, 2005 ²⁶⁹	OPERA (Overactive bladder: Performance of Extended Release Agents) trial	Double-blind	Yes	Unclear	Adequate	No
Dmochowski, 2002 ²⁷¹	Transdermal Oxybutynin Study Group	Double-blind	No	Unclear	Adequate	Yes
Dmochowski, 2008 ²⁷²	RCT	Double-blind	Not stated	Unclear	Adequate	No
Dmochowski, 2005 ²⁷³	Transdermal Oxybutynin Study Group.	Double-blind	Yes	Previously reported ^{271,274}	Previously reported ^{271,274}	Previously reported ^{271,274}
Dmochowski, 2003 ²⁷⁴	Transdermal Oxybutynin Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Dmochowski, 2003 ²⁷⁵	Duloxetine Urinary Incontinence Study Group	Double-blind	Yes	Adequate	Adequate	Yes
Dmochowski, 2007 ²⁷⁶	RCT	Double-blind	Yes	Previously reported	Previously reported	Previously reported
Dmochowski, 2010 ³⁷²	RCT	Double-blind	Yes	Reported previously ^{272,404}	Adequate	Yes
Dmochowski, 2010 ²⁷⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Dorschner, 2000 ²⁷⁸	RCT	Double-blind	No	Unclear	Adequate	No
Drutz, 1999 ²⁷⁹	RCT	Double-blind	No	NR	Adequate	Yes
DuBeau, 2005 ²⁸⁰	RCT analysis	Double-blind	No	Adequate	Adequate	Yes
Duckett, 2007 ²⁸¹	Observational study	Open label	No	Not relevant	Not relevant	No
Enzelsberger, 1995 ²⁸²	RCT	Open label	NR	Adequate	Adequate	No
Fitzgerald, 2008 ²⁴⁰	Urinary Incontinence Treatment Network.	Open label	Yes	Unclear	Not reported	Yes
Flynn, 2009 ²⁸³	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Foote, 2005 ²⁸⁴	Pooled	Double-blind	Yes	Unclear	Adequate	No
Franzen, 2010 ²⁸⁵	RCT	Open label	Yes	Adequate	Adequate	Yes
Freeman, 2003 ²⁸⁶	RCT analysis	Double-blind	No	Adequate	No	Previously reported ³³¹
Gahimer, 2007 ²⁸⁷	The duloxetine exposures integrated safety database	Open label	Yes	Previously reported ^{275,350,354,411}	Not relevant	No
Ghei, 2005 ²⁸⁸	RCT	Double-blind	Yes	Adequate	Not reported	Yes
Ghoniem, 2005 ²⁸⁹	Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group	Double-blind	Yes	Adequate	Adequate	Yes
Gleason, 1999 ³⁴²	Ditropan XL Study Group, non RCT	Open label	No	Not relevant	Not relevant	No
Goode, 2002 ²⁹⁰	RCT	Double-blind	No	NR	Adequate	No
Goode, 2004 ²⁹¹	RCT analysis	Double-blind	No	NR	Not reported	No
Gupta, 1999 ²⁹²	RCT	Open label	No	NR	Not reported	No
Gupta, 1999 ²⁹³	Pooled	Double-blind	Not reported	NR	Not reported	No
Gousse, 2010 ²⁹⁴	RCT	NR	NR	NR	Adequate	NR
Haab, 2006 ²⁹⁵	RCT analysis	Open label	Yes	RCT analysis	RCT analysis	No
Haab, 2005 ²⁹⁷	RCT analysis	Open label	Yes	Previously reported ⁵²	Previously reported ⁵²	Previously reported ⁵²
Haab, 2004 ²⁹⁶	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Halaska, 2003 ²⁹⁸	RCT	Double-blind	Yes	Unclear	Adequate	No
Herschorn, 2004 ²⁹⁹	RCT	Open label	Yes	Adequate	No	No
Herschorn, 2010 ³⁰⁰	VECTOR	Double-blind	Yes	NR	Adequate	Yes
Herschorn, 2008 ³⁰¹	RCT	Double-blind	Yes	NR	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Hill, 2006 ⁴²	Darifenacin Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Ho, 2010 ³⁰²	RCT	Open label	Yes	Unclear	Adequate	NR
Holtedahl, 2000 ³⁰³	RCT analysis	NR	Yes	Not adequate	Adequate	Reported previously ³⁰⁴
Holtedahl, 1998 ³⁰⁴	RCT	Not reported	No	Unclear	Adequate	Yes
Homma, 2006 ³⁰⁵	RCT analysis	Double-blind	No	NR	Adequate	No
Homma, 2004 ³⁰⁶	RCT	Double-blind	Yes	NR	No	No
Homma, 2003 ³⁰⁷	Japanese and Korean Tolterodine Study Group	Double-blind	Yes	NR	Adequate	Yes
Hurley, 2006 ³⁰⁸ Viktrup, 2007 ³⁰⁹	Duloxetine Urinary Incontinence Study Group	Double-blind	No	Previously reported ^{275,350,354,411}	Not reported	Pooled analysis
Ishiko, 2001 ³¹⁰	RCT	Open label	No	Unclear	Adequate	No
Jackson, 1999 ³¹¹	RCT	Double-blind	NR	Not reported	Adequate	Yes
Jacquetin, 2001 ³¹²	RCT	Double-blind	Yes	Unclear	No	Yes
Johnson, 2005 ³¹³	RCT analysis	Double-blind	NR	Adequate	Adequate	Yes
Jonas, 1997 ³¹⁴	International Study Group	Double-blind	Not stated	Unclear	Adequate	No
Junemann, 2000 ³¹⁶	RCT	Double-blind	No	NR	NR	NR
Junemann, 2005 ³¹⁷	RCT	Double-blind	Yes	Unclear	Not reported	No
Junemann, 2006 ³¹⁵	RCT	Double-blind	No	NR	NR	NR
Kaplan, 2010 ³¹⁸	RCT	Double-blind	NR	NR	NR	Yes
Karademir, 2005 ³¹⁹	RCT	Open label	No	NR	Adequate	No
Karram, 2009 ³²⁰	VENUS	Double-blind	No	NR	Adequate	Yes
Kelleher, 2006 ³²²	RCT	Double-blind	No	Previously reported ⁵²	Previously reported ⁵²	No
Kelleher, 2002 ³²³	RCT	Double-blind	Yes	Unclear	Adequate	No
Kelleher, 2008 ³²⁴	Pooled analysis	Double-blind	NR	Unclear	Adequate	NR
van Kerrebroeck, 2004 ⁴¹¹	Duloxetine Urinary Incontinence Study Group.	Double-blind	Yes	Adequate	No	Yes
Van Kerrebroeck, 2001 ³³¹	Tolterodine Study Group.	Double-blind	Yes	Unclear	Adequate	No

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Khullar, 2004 ³²⁵	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Khullar, 2008 ³²⁶	Pooled	Double-blind	Yes	Previously reported ^{253,353}	Previously reported ^{253,353}	Previously reported ^{253,353}
Kinchen, 2005 ³²⁷	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Kreder, 2003 ³²⁸	RCT analysis	Single blind	No	Unclear	Adequate	No
Lackner, 2008 ³²⁹	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Landis, 2004 ³³⁰	RCT	Double-blind	No	Previously reported ⁴⁰⁸	No	Previously reported ⁴⁰⁸
Lee, 2002 ³³²	RCT	Double-blind	Yes	Not reported	Adequate	No
Lee, 2010 ³³³	Propiverine study on overactive bladder including urgency data	Double-blind	No	Not adequate	Adequate	Yes
Lehtoranta, 2002 ³³⁴	RCT	Double-blind	Yes	NR	NR	No
Leung, 2002 ³³⁵	RCT	Open label	Yes	NR	Adequate	Yes
Lin, 2008 ³³⁶	RCT	Double-blind	Yes	Adequate	No	Yes
Lipton, 2005 ³³⁷	RCT	Double-blind	No	Unclear	NR	Yes
Lose, 2000 ³³⁸	RCT	Open label	Yes	Unclear	Adequate	Yes
MacDiarmid, 2005 ³³⁹	Pooled	2 Double-blind and one open label	Yes	Previously reported ^{40,340-342}	Previously reported ^{40,340-342}	Previously reported ^{40,340-342}
Madersbacher, 1999 ³⁴³	RCT	Double-blind	Yes	NR	Adequate	No
Malhotra, 2010 ³⁴⁴	RCT	Double-blind	Yes	NR	Not adequate	Yes
Malone-Lee, 2009 ³⁴⁵	RCT	Double-blind	No	Unclear	Adequate	Yes
Malone-Lee, 2009 ³⁴⁶	RCT	Double-blind	Yes	Adequate	No	No
Mattiasson, 2009 ⁶¹	SOLAR	Single blind	Yes	NR	Adequate	Yes
Mattiasson, 2003 ³⁴⁷	RCT Tolterodine Scandinavian Study Group	Single blind	Yes	Adequate	Adequate	Yes
Milani, 1993 ³⁴⁸	RCT	Double-blind	No	Unclear	NR	No
Millard, 1999 ³⁴⁹	RCT	Double-blind	Yes	Unclear	No	Yes
Millard, 2004 ³⁵⁰	Duloxetine UI Study Group	Double-blind	Yes	Adequate	No	Yes
Moore, 1990 ³⁵¹	RCT	Double-blind	No	Adequate	Adequate	NR
Naglie, 2002 ³⁵²	RCT	Double-blind	Yes	Unclear	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
NCT00269750, 2005 ⁵⁵	RCT	Double-blind	NR	NR	NR	NR
NCT00168454, 2008 ⁵³	RCT	Double-blind	NR	NR	NR	NR
NCT00444925 ⁵⁶	RCT	Double-blind	NR	NR	NR	NR
NCT00536484 ⁵⁷	RCT	Double-blind	NR	NR	NR	NR
NCT00178191 ⁵⁴	RCT	Double-blind	NR	NR	NR	NR
Nitti C, 2007 ³⁵³	RCT	Double-blind	No	Adequate	Adequate	No
Norton, 2002 ³⁵⁴ Sahai, 2006 ³⁵⁵	Duloxetine Urinary Incontinence Study Group.	Double-blind	Yes	Adequate	Adequate	Yes
Ozdedeli, 2010 ³⁵⁶	RCT	Open-label	No	Not adequate	Adequate	NR
Peters, 2009 ³⁵⁷	Overactive Bladder Innovative Therapy	Open label	No	Unclear	Adequate	Yes
Pontari, 2010 ³⁵⁹	RCT	Double-blind	Yes	NR	Not adequate	No
Preik, 2004 ³⁴⁰	RCT	Double-blind	No	Not reported	Adequate	No
Rentzhog, 1998 ³⁶⁰	RCT	Double-blind	No	NR	Adequate	Yes
Richter, 2010 ³⁶¹	ATLAS	Open label	Yes	Not adequate	Adequate	Yes
Robinson, 2007 ³⁶³	The Tamsulosin Study Group	Double-blind	No	Adequate	Adequate	Yes
Rogers, 2009 ³⁶⁴	RCT	Double-blind	No	NR	Adequate	NR
Rogers, 2009 ³⁶⁶	RCT	Open label	No	Previously reported ^{364,365}	Previously reported ^{364,365}	Previously reported ^{364,365}
Rogers, 2008 ³⁶⁵	RCT	Double-blind	No	Unclear	Adequate	Yes
Rudy, 2006 ³⁶⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Rudy, 2006 ³⁴	RCT analysis	Double-blind	Yes	Unclear	Adequate	Yes
Rufford, 2003 ³⁶⁸	RCT	Double-blind	No	Adequate	Adequate	Yes
Salvatore, 2005 ³⁶⁹	RCT	Open label	No	NR	NR	Yes
Sand, 2009 ³⁷⁰	Pooled	Double-blind	No	Previously reported ^{253, 254,353}	Adequate	No
Sand, 2004 ²²⁶	RCT	Double-blind	Yes	NR	Adequate	No
Sand, 2009 ³⁷¹	Pooled	Double-blind	Yes	Unclear	Adequate	Previously reported ^{45,272}
Sand, 2006 ³⁷³ Sand, 2007 ³⁷⁴	Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial	Open label	Yes	Not adequate	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Sand, 2011 ³⁷⁵	RCT	Double-blind	Yes	Adequate	Not adequate (for the subgroup analysis)	NR
Scarpero, 2011 ³⁷⁶	Post-hoc, pooled subset analysis	Open-label	No	Unclear	Adequate	NR
Schagen van Leeuwen, 2008 ³⁷⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Staskin, 2006 ³⁷	Pooled	Double-blind	No	Previously reported ^{396,412}	Not reported	Previously reported ⁴¹²
Staskin, 2007 ⁴⁵	Trospium Study Group	Double-blind	Yes	Adequate	Adequate	Yes
Staskin, 2004 ³⁷⁸	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Staskin, 2009 ³¹	RCT	Double-blind	Yes	Not reported	Adequate	Yes
Staskin, 2009 ³⁷⁹	Post-hoc	Double-blind	Yes	Reported previously ^{272,404}	Adequate	NR
Staskin, 2009 ⁴⁹	RCT	Double-blind	Yes	NR	Adequate	Yes
Staskin, 2009 ⁴⁹	Pooled analysis of individual patient data	Not reported	Yes	Not reported	Adequate	Not reported
Steers, 2005 ⁴³	RCT	Double-blind	No	Unclear	Adequate	Yes
Steers, 2007 ³⁸⁰	Duloxetine OAB Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Swift, 2003 ³⁸¹	Tolterodine Study Group	Double-blind	Yes	Unclear	Adequate	No
Szonyi, 1995 ³⁸²	RCT	Double-blind	No	NR	Adequate	Yes
Takei, 2005 ³⁸³	Japanese Tolterodine Study Group.	Combination	Yes	NR	Adequate	No
Tapp, 1990 ³⁸⁴	RCT	Double-blind	No	Adequate	Adequate	Yes
Tincello, 2000 ³⁸⁵	RCT	Open label	Not reported	Adequate	Not adequate	Yes
Thuroff, 1991 ³⁸⁶	RCT	Double-blind	No	Adequate	Adequate	NR
Toglia, 2009 ³²¹	VENUS	Double-blind	No	NR	Adequate	Yes
Toglia, 2010 ³⁸⁷	Post-hoc VENUS	Double-blind	NR	Unclear	Not adequate	Previously reported ^{320,321}
U.S. Food and Drug Administration, 2004 ³⁸⁹	RCT	Double-blind	NR	NR	NR	NR
U.S. Food and Drug Administration, 2004 ³³	RCT	Double-blind	NR	NR	NR	NR

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
U.S. Food and Drug Administration, 2004 ⁴¹	RCT	Double-blind	Yes	NR	NR	NR
Pharmaceutical Research and Manufacturers of America ⁵⁹	SUNRISE	Double-blind	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration, 2004 ³⁹⁰	RCT	Double-blind	Yes	NR	NR	NR
U.S. Food and Drug Administration, 1998 ³⁹	RCT	Double-blind	NR	NR	NR	Yes
Pharmaceutical Research and Manufacturers of America ⁶²	SOLAR	Single blind	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration, 2007 ³⁸	RCT	12 weeks double-blind followed by 9 months open-label	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration, 2007 ⁴⁴	RCT	12 weeks double-blind followed by 9 months open-label	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration ²⁵⁷	STAR	Double-blind	NR	NR	Adequate	NR
Van Kerrebroeck, 2010 ³⁹¹	Subgroup analysis of pooled data	Open-label	Yes	Reported previously ²⁵³	NA	NR
Vardy, 2009 ³⁹²	VIBRANT	Double-blind	No	Not reported	Adequate	Yes
Vella, 2008 ³⁹³	Not RCT	Open label	No	Not relevant	Not relevant	No
Versi, 2000 ⁴⁰	Ditropan XL Study Group	Double-blind	Not reported	Adequate	No	No
von Holst ³⁹⁴	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Waetjen, 2005 ³⁹⁵	RCT	Double-blind	Yes	Adequate	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Wagg, 2006 ³⁹⁶	pooled analysis	4 double-blind studies and one open-label	NR	NR	NR	NR
Wang, 2006 ⁴¹³	RCT	Single blind	No	Not adequate	Adequate	Yes
Wang, 2009 ³⁹⁷	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Mazur, 1995 ³⁹⁸	RCT	Open label	No	Unclear	Not reported	No
Wein, 2007 ³⁹⁹	RCT analysis	Double-blind	Yes	Previously reported ^{323,408}	Adequate	No
Weinstein, 2006 ⁴⁰⁰	DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations).	Open label	Yes	Unclear	Not adequate	No
Yalcin, 2006 ⁴⁰¹	Pooled	Double-blind	Yes	Previously reported ^{275,354}	Previously reported ^{275,354}	Previously reported ^{275,354}
Yalcin, 2004 ⁴⁰²	Duloxetine UI Study Group	Double-blind	Yes	Previously reported ^{275,350,354,411}	Adequate	Pooled analysis
Yamaguchi, 2007 ⁴⁰³	RCT	Double-blind	No	NR	Adequate	Yes
Zellner, 2009 ⁴⁰⁴	RCT	Double-blind	Yes	Not adequate	Adequate	Yes
Zinner, 2005 ⁴⁰⁵	RCT	Double-blind	No	Unclear	Adequate	Yes
Zinner, 2008 ⁴⁰⁶	RCT	Open label	No	Unclear	NR	Yes
Zinner, 2006 ⁴⁰⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Zinner, 2004 ³⁵	Trospium Study Group	Double-blind	Yes	Unclear	Adequate	No
Zinner, 2002 ⁴⁰⁸	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Zinner, 2005 ⁴⁰⁹	Pooled	Double-blind	Yes	Previously reported ^{34,35,367}	Adequate	No
Zinner, 2011 ⁴¹⁰	Open-label of RCT	Open-label	No	Reported previously ^{45,272}	Adequate	NR

Abbreviation: NR = Not reported